Abstract
The identification of oncogenic genomic alterations is expected to facilitate the development of new molecularly targeted therapies for cancer. EML4 (echinoderm microtubule-associated protein-like 4)-ALK (anaplastic lymphoma kinase) was recently identified as a transforming fusion gene in non-small cell lung cancer (NSCLC). A small-molecule tyrosine kinase inhibitor of ALK, crizotinib, shows pronounced clinical activity in the treatment of patients with NSCLC positive for EML4-ALK, and it has rapidly entered into daily clinical practice. This review focuses on the biology and clinical features of, as well as diagnostic testing for, EML4-ALK-positive NSCLC. Current data on the efficacy and toxicity of crizotinib are also examined, and future directions for the treatment of NSCLC positive for ALK rearrangement are addressed.
References
Jul 13, 2007·Nature·Manabu SodaHiroyuki Mano
Dec 18, 2007·Cell·Klarisa RikovaMichael J Comb
Jan 2, 2008·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Kentaro InamuraYuichi Ishikawa
Oct 18, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Kengo TakeuchiHiroyuki Mano
Nov 18, 2008·Cancer Research·Seiji YanoSaburo Sone
Nov 27, 2008·Cancer Science·Hiroyuki Mano
Dec 10, 2008·Proceedings of the National Academy of Sciences of the United States of America·Manabu SodaHiroyuki Mano
Apr 23, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Kengo TakeuchiHiroyuki Mano
Nov 20, 2009·The FEBS Journal·Isamu Okamoto
Dec 22, 2009·The Lancet Oncology·Tetsuya MitsudomiUNKNOWN West Japan Oncology Group
Apr 27, 2010·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Takaaki SasakiPasi A Jänne
Aug 19, 2010·Molecular Cancer Therapeutics·Wataru OkamotoKazuhiko Nakagawa
Oct 29, 2010·The New England Journal of Medicine·Eunice L KwakA John Iafrate
Oct 29, 2010·The New England Journal of Medicine·Young Lim ChoiUNKNOWN ALK Lung Cancer Study Group
Dec 17, 2010·Cancer Research·Kunio OkamotoKazuhiko Nakagawa
Mar 19, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ken TakezawaKazuhiko Nakagawa
May 18, 2011·Cancer Cell·Hiroshi SakamotoYuko Aoki
Jul 27, 2011·Therapeutic Advances in Medical Oncology·Isamu OkamotoMasahiro Fukuoka
Jul 28, 2011·Cancer Research·Takaaki SasakiPasi A Jänne
Sep 9, 2011·Science Translational Medicine·Kimio YonesakaPasi A Jänne
Sep 22, 2011·The Lancet Oncology·Alice T ShawD Ross Camidge
Nov 16, 2011·Therapeutic Advances in Medical Oncology·Yung-Jue Bang
Jan 14, 2012·British Journal of Cancer·J TanizakiK Nakagawa
Citations
Mar 5, 2013·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Matthias PreusserPeter Birner
Nov 20, 2012·Clinica Chimica Acta; International Journal of Clinical Chemistry·Akane SuekiTakayuki Honda
Oct 20, 2017·European Journal of Endocrinology·André Uchimura BastosJanete Maria Cerutti
Jul 5, 2019·Veterinary Surgery : VS·Scarlett M SumnerGary W Ellison
Oct 31, 2018·Journal of Cellular Physiology·Gui-Feng LiuShu-Hua Zhang
Aug 13, 2013·The Journal of Biological Chemistry·John D HarlingRoberto Solari
Mar 9, 2018·The EPMA Journal·Miaolong Lu, Xianquan Zhan
Sep 22, 2020·Expert Opinion on Drug Delivery·Archana UpadhyaAmbikanandan Misra
May 29, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Keiichi OtaIsamu Okamoto
Mar 7, 2021·Cancers·David KönigSacha I Rothschild